CAREMM-014NCT07903623
QLS4131 Plus Isatuximab in Newly Diagnosed Primary Plasma Cell Leukemia
StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Minimal residual disease (MRD) negative rate
Timeframe: After 9 cycles (each cycle is 28 days)
Secondary (6)
Incidence and severity of adverse events (AEs)
Duration of MRD negativity
Overall Response Rate (ORR)
Complete Response Rate (CRR)
Progression-free survival (PFS)
Show 1 moreShow less
Overall survival (OS)
Arms and interventions
QLS4131 Plus IsatuximabExperimental
Participants will receive QLS4131 in combination with isatuximab for up to 18 cycles, with each cycle lasting 28 days.
Drugs: QLS4131, Isatuximab
Sites
1 site in 1 country
- Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical SciencesTianjin, Tianjin Municipality, China